Twelve Reasons for Considering Buprenorphine as a Frontline Analgesic in the Management of Pain

Journal of Supportive Oncology

Volumn 10, Issue 6, 2012, Pages 209-219

  Davis, Mellar P ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BUPRENORPHINE; CORTICOSTEROID; DIHYDROMORPHINE; DRUG METABOLITE; FENTANYL; IMMUNOSUPPRESSIVE AGENT; METHADONE; MORPHINE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE DERIVATIVE; OXYCODONE; PLACEBO;

ANALGESIA; CANCER PAIN; CHRONIC PAIN; COGNITIVE DEFECT; CONSTIPATION; DIALYSIS; DISEASE SEVERITY; DRUG ACCUMULATION; DRUG CHOICE; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG WITHDRAWAL; HUMAN; HYPERALGESIA; HYPOGONADISM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE DEFICIENCY; KIDNEY FAILURE; LD 50; LOW DRUG DOSE; MALE SEXUAL DYSFUNCTION; NAUSEA; NEUROPATHIC PAIN; NONHUMAN; ODDI SPHINCTER; OPIATE ADDICTION; PAIN; PHENOTYPE; QT PROLONGATION; RESPIRATION DEPRESSION; REVIEW; SIDE EFFECT; SUDDEN DEATH; VOMITING; WITHDRAWAL SYNDROME;

ANALGESICS, OPIOID; BUPRENORPHINE; DRUG TOLERANCE; GERIATRICS; HUMANS; NEOPLASMS; NEURALGIA; OPIOID-RELATED DISORDERS; PAIN; RECEPTORS, OPIOID, MU; RENAL INSUFFICIENCY;

EID: 84869123827     PISSN: 15446794     EISSN: 1879596X     Source Type: Journal    
DOI: 10.1016/j.suponc.2012.05.002     Document Type: Review

References (217)

1. Lutfy K., Cowan A. Buprenorphine: a unique drug with complex pharmacology. Curr Neuropharmacol 2004, 2(4):395-402.
2. Pergolizzi J., Aloisi A.M., Dahan A., et al. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract 2010, 10(5):428-450.
3. Vadivelu N., Hines R.L. Management of chronic pain in the elderly: focus on transdermal buprenorphine. Clin Interv Aging 2008, 3(3):421-430.
4. Budd K., Collett B.J. Old dog-new (ma)trix. Br J Anaesth 2003, 90(6):722-724.
5. Budd K. Buprenorphine and the transdermal system: the ideal match in pain management. Int J Clin Pract Suppl 2003, (133):9-14. 23-24.
6. Freye E., Anderson-Hillemacher A., Ritzdorf I., Levy J.V. Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients. Pain Pract 2007, 7(2):123-129.
7. Sittl R., Nuijten M., Nautrup B.P. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study. Clin Ther 2005, 27(7):1022-1031.
8. Mercadante S., Casuccio A., Tirelli W., Giarratano A. Equipotent doses to switch from high doses of opioids to transdermal buprenorphine. Support Care Cancer 2009, 17(6):715-718.
9. Christoph T., Kögel B., Schiene K., Meén M., De Vry J., Friderichs E. Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain. Eur J Pharmacol 2005, 507(1-3):87-98.
10. Kress H.G. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain 2009, 13(3):219-230.
11. Wheeler-Aceto H., Cowan A. Buprenorphine and morphine cause antinociception by different transduction mechanisms. Eur J Pharmacol 1991, 195(3):411-413.
12. Ocaña M., Del Pozo E., Barrios M., Baeyens J.M. Subgroups among mu-opioid receptor agonists distinguished by ATP-sensitive K+ channel-acting drugs. Br J Pharmacol 1995, 114(6):1296-1302.
13. Sánchez-Blázquez P., Gómez-Serranillos P., Garzón J. Agonists determine the pattern of G-protein activation in mu-opioid receptor-mediated supraspinal analgesia. Brain Res Bull 2001, 54(2):229-235.
14. Saidak Z., Blake-Palmer K., Hay D.L., Northup J.K., Glass M. Differential activation of G-proteins by mu-opioid receptor agonists. Br J Pharmacol 2006, 147(6):671-680.
15. Lee C.W., Yan J.Y., Chiang Y.C., et al. Differential pharmacological actions of methadone and buprenorphine in human embryonic kidney 293 cells coexpressing human mu-opioid and opioid receptor-like 1 receptors. Neurochem Res 2011, 36(11):2008-2021.
16. Pergolizzi J., Böger R.H., Budd K., et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 2008, 8(4):287-313.
17. Zaki P.A., Keith D.E., Brine G.A., Carroll F.I., Evans C.J. Ligand-induced changes in surface mu-opioid receptor number: relationship to G protein activation?. J Pharmacol Exp Ther 2000, 292(3):1127-1134.
18. Cowan A., Doxey J.C., Harry E.J. The animal pharmacology of buprenorphine, an oripavine analgesic agent. Br J Pharmacol 1977, 60(4):547-554.
19. Brown E.E., Finlay J.M., Wong J.T., Damsma G., Fibiger H.C. Behavioral and neurochemical interactions between cocaine and buprenorphine: implications for the pharmacotherapy of cocaine abuse. J Pharmacol Exp Ther 1991, 256(1):119-126.
20. Ciccocioppo R., Angeletti S., Panocka I., Massi M. Nociceptin/orphanin FQ and drugs of abuse. Peptides 2000, 21(7):1071-1080.
21. Ciccocioppo R., Angeletti S., Sanna P.P., Weiss F., Massi M. Effect of nociceptin/orphanin FQ on the rewarding properties of morphine. Eur J Pharmacol 2000, 404(1-2):153-159.
22. Kuhlman J.J., Lalani S., Magluilo J., Levine B., Darwin W.D. Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. J Anal Toxicol 1996, 20(6):369-378.
23. Nath R.P., Upton R.A., Everhart E.T., et al. Buprenorphine pharmacokinetics: relative bioavailability of sublingual tablet and liquid formulations. J Clin Pharmacol 1999, 39(6):619-623.
24. Mendelson J., Upton R.A., Everhart E.T., Jacob P., Jones R.T. Bioavailability of sublingual buprenorphine. J Clin Pharmacol 1997, 37(1):31-37.
25. Bullingham R.E., McQuay H.J., Moore A., Bennett M.R. Buprenorphine kinetics. Clin Pharmacol Ther 1980, 28(5):667-672.
26. Brewster D., Humphrey M.J., McLeavy M.A. Biliary excretion, metabolism and enterohepatic circulation of buprenorphine. Xenobiotica 1981, 11(3):189-196.
27. Heel R.C., Brogden R.N., Speight T.M., Avery G.S. Buprenorphine: a review of its pharmacological properties and therapeutic efficacy. Drugs 1979, 17(2):81-110.
28. Zhang W., Ramamoorthy Y., Tyndale R.F., Sellers E.M. Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. Drug Metab Dispos 2003, 31(6):768-772.
29. Umehara K., Shimokawa Y., Miyamoto G. Inhibition of human drug metabolizing cytochrome P450 by buprenorphine. Biol Pharm Bull 2002, 25(5):682-685.
30. Kintz P. A new series of 13 buprenorphine-related deaths. Clin Biochem 2002, 35(7):513-516.
31. Johnson R.E., Fudala P.J., Payne R. Buprenorphine: considerations for pain management. J Pain Symptom Manage 2005, 29(3):297-326.
32. Cone E.J., Gorodetzky C.W., Yousefnejad D., Buchwald W.F., Johnson R.E. The metabolism and excretion of buprenorphine in humans. Drug Metab Dispos 1984, 12(5):577-581.
33. Clarot F., Proust B., Vaz E., Goullé J.P. Tramadol-benzodiazepines and buprenorphine-benzodiazepines: two potentially fatal cocktails?. J Clin Forensic Med 2003, 10(2):125-126.
34. Tegeder I., Lötsch J., Geisslinger G. Pharmacokinetics of opioids in liver disease. Clin Pharmacokinet 1999, 37(1):17-40.
35. Brown S.M., Holtzman M., Kim T., Kharasch E.D. Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active. Anesthesiology 2011, 115(6):1251-1260.
36. Gueye P.N., Borron S.W., Risede P., et al. Buprenorphine and midazolam act in combination to depress respiration in rats. Toxicol Sci 2002, 65(1):107-114.
37. Yassen A., Olofsen E., Romberg R., et al. Mechanism-based PK/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers. Clin Pharmacol Ther 2007, 81(1):50-58.
38. Ohtani M., Kotaki H., Nishitateno K., Sawada Y., Iga T. Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine. J Pharmacol Exp Ther 1997, 281(1):428-433.
39. Pergolizzi J.V., Mercadante S., Echaburu A.V., et al. The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus. Curr Med Res Opin 2009, 25(6):1517-1528.
40. Shaheen P.E., Legrand S.B., et al. Errors in opioid prescribing: a prospective survey in cancer pain. J Pain Symptom Manage 2010, 39(4):702-711.
41. Estfan B., LeGrand S.B., Walsh D., Lagman R.L., Davis M.P. Opioid rotation in cancer patients: pros and cons. Oncology (Williston Park) 2005, 19(4):511-516. discussion 516-518, 521-523, 527-528.
42. Reddy R.G., Aung T., Karavitaki N., Wass J.A. Opioid induced hypogonadism. BMJ 2010, 341:c4462.
43. Davis M. Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics. Clin Pharmacokinet 2007, 46(10):825-850.
44. Dean M. Opioids in renal failure and dialysis patients. J Pain Symptom Manage 2004, 28(5):497-504.
45. Cachia E., Ahmedzai S.H. Transdermal opioids for cancer pain. Curr Opin Support Palliat Care 2011, 5(1):15-19.
46. Erroneous downstream occlusion alarms may disable Smiths Medical CADD-Solis infusion pumps. Health Devices 2010, 39(10):380-381. User experience network.
47. Patient-controlled analgesic infusion pumps. Evaluating the Deltec CADD-Prizm PCS II. Health Devices 2001, 30(9-10):360-364.
48. Improper cassette attachment allows gravity free-flow from SIMS-Deltec CADD-series pumps. Health Devices 1995, 24(2):84-86.
49. Davis M.P. Buprenorphine in cancer pain. Support Care Cancer 2005, 13(11):878-887.
50. Przeklasa-Muszyńska A., Dobrogowski J. Transdermal buprenorphine in the treatment of cancer and non-cancer pain-the results of multicenter studies in Poland. Pharmacol Rep 2011, 63(4):935-948.
51. Przeklasa- Muszyńska A., Dobrogowski J. Transdermal buprenorphine for the treatment of moderate to severe chronic pain: results from a large multicenter, non-interventional post-marketing study in Poland. Curr Med Res Opin 2011, 27(6):1109-1117.
52. Likar R., Sittl R. Transdermal buprenorphine for treating nociceptive and neuropathic pain: four case studies. Anesth Analg 2005, 100(3):781-785.
53. Griessinger N., Sittl R., Likar R. Transdermal buprenorphine in clinical practice-a post-marketing surveillance study in 13,179 patients. Curr Med Res Opin 2005, 21(8):1147-1156.
54. Sittl R. Transdermal buprenorphine in cancer pain and palliative care. Palliat Med 2006, 20(suppl 1):S25-S30.
55. Muriel C., Failde I., Micó J.A., Neira M., Sánchez-Magro I. Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study. Clin Ther 2005, 27(4):451-462.
56. Brema F., Pastorino G., Martini M.C., et al. Oral tramadol and buprenorphine in tumour pain. An Italian multicentre trial. Int J Clin Pharmacol Res 1996, 16(4-5):109-116.
57. Noda J., Umeda S., Arai T., Harima A., Mori K. Continuous subcutaneous infusion of buprenorphine for cancer pain control. Clin J Pain 1989, 5(2):147-152.
58. Ventafridda V., De Conno F., Guarise G., Tamburini M., Savio G. Chronic analgesic study on buprenorphine action in cancer pain. Comparison with pentazocine. Arzneimittelforschung 1983, 33(4):587-590.
59. Robbie D.S. A trial of sublingual buprenorphine in cancer pain. Br J Clin Pharmacol 1979, 7(suppl 3):S315-S317.
60. Mercadante S., Porzio G., Ferrera P., et al. Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: a 4-week, nonrandomized, open-label, uncontrolled observational study. Clin Ther 2009, 31(10):2134-2138.
61. Wolff R.F., Aune D., Truyers C., et al. Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain. Curr Med Res Opin 2012, 28(5):833-845.
62. LaMotte R.H., Shain C.N., Simone D.A., Tsai E.F. Neurogenic hyperalgesia: psychophysical studies of underlying mechanisms. J Neurophysiol 1991, 66(1):190-211.
63. Nahman-Averbuch H., Yarnitsky D., Granovsky Y., et al. Pronociceptive pain modulation in patients with painful chemotherapy-induced polyneuropathy. J Pain Symptom Manage 2011, 42(2):229-238.
64. Heinricher M.M., McGaraughty S., Grandy D.K. Circuitry underlying antiopioid actions of orphanin FQ in the rostral ventromedial medulla. J Neurophysiol 1997, 78(6):3351-3358.
65. Koppert W., Ihmsen H., Körber N., et al. Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model. Pain 2005, 118(1-2):15-22.
66. Kouya P.F., Hao J.X., Xu X.J. Buprenorphine alleviates neuropathic pain-like behaviors in rats after spinal cord and peripheral nerve injury. Eur J Pharmacol 2002, 450(1):49-53.
67. Hans G. Buprenorphine-a review of its role in neuropathic pain. J Opioid Manag 2007, 3(4):195-206.
68. Koppert W., Dern S.K., Sittl R., Albrecht S., Schϋttler J., Schmelz M. A new model of electrically evoked pain and hyperalgesia in human skin: the effects of intravenous alfentanil, S(+)-ketamine, and lidocaine. Anesthesiology 2001, 95(2):395-402.
69. Célèrier E., Rivat C., Jun Y., et al. Long-lasting hyperalgesia induced by fentanyl in rats: preventive effect of ketamine. Anesthesiology 2000, 92(2):465-472.
70. Bouhassira D., Villanueva L., Le Bars D. Intracerebroventricular morphine decreases descending inhibitions acting on lumbar dorsal horn neuronal activities related to pain in the rat. J Pharmacol Exp Ther 1988, 247(1):332-342.
71. Le Bars D., Willer J.C., De Broucker T. Morphine blocks descending pain inhibitory controls in humans. Pain 1992, 48(1):13-20.
72. Dickenson A.H., Le Bars D. Morphine microinjections into periaqueductal grey matter of the rat: effects on dorsal horn neuronal responses to C-fibre activity and diffuse noxious inhibitory controls. Life Sci 1983, 33(suppl 1):S549-S552.
73. Le Bars D., Chitour D., Kraus E., Clot A.M., Dickenson A.H., Besson J.M. The effect of systemic morphine upon diffuse noxious inhibitory controls (DNIC) in the rat: evidence for a lifting of certain descending inhibitory controls of dorsal horn convergent neurones. Brain Res 1981, 215(1-2):257-274.
74. Le Bars D., Villanueva L., Bouhassira D., Willer J.C. Diffuse noxious inhibitory controls (DNIC) in animals and in man. Patol Fiziol Eksp Ter 1992, (4):55-65.
75. Wen Z.H., Chang Y.C., Wong C.S. Implications of intrathecal pertussis toxin animal model on the cellular mechanisms of neuropathic pain syndrome. Acta Anaesthesiol Sin 2003, 41(4):187-196.
76. Womer D.E., DeLapp N.W., Shannon H.E. Intrathecal pertussis toxin produces hyperalgesia and allodynia in mice. Pain 1997, 70(2-3):223-228.
77. McCormack K., Prather P., Chapleo C. Some new insights into the effects of opioids in phasic and tonic nociceptive tests. Pain 1998, 78(2):79-98.
78. Guetti C., Angeletti C., Marinangeli F., et al. Transdermal buprenorphine for central neuropathic pain: clinical reports. Pain Pract 2011, 11(5):446-452.
79. Induru R.R., Davis M.P. Buprenorphine for neuropathic pain-targeting hyperalgesia. Am J Hosp Palliat Care 2009, 26(6):470-473.
80. Louis F. Transdermal buprenorphine in pain management-experiences from clinical practice: Five case studies. Int J Clin Pract 2006, 60(10):1330-1334.
81. Likar R., Krainer B., Sittl R. Challenging the equipotency calculation for transdermal buprenorphine: four case studies. Int J Clin Pract 2008, 62(1):152-156.
82. Penza P., Campanella A., Martini A., et al. Short- and intermediate-term efficacy of buprenorphine TDS in chronic painful neuropathies. J Peripher Nerv Syst 2008, 13(4):283-288.
83. Benedetti F., Vighetti S., Amanzio M., et al. Dose-response relationship of opioids in nociceptive and neuropathic postoperative pain. Pain 1998, 74(2-3):205-211.
84. Andresen T., Upton R.N., Foster D.J., Christrup L.L., Arendt-Nielsen L., Drewes A.M. Pharmacokinetic/pharmacodynamic relationships of transdermal buprenorphine and fentanyl in experimental human pain models. Basic Clin Pharmacol Toxicol 2011, 108(4):274-284.
85. Koltzenburg M., Pokorny R., Gasser U.E., Richarz U. Differential sensitivity of three experimental pain models in detecting the analgesic effects of transdermal fentanyl and buprenorphine. Pain 2006, 126(1-3):165-174.
86. Vanderah T.W., Gardell L.R., Burgess S.E., et al. Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance. J Neurosci 2000, 20(18):7074-7079.
87. Bouhassira D., Villanueva L., Le Bars D. Effects of systemic morphine on diffuse noxious inhibitory controls: role of the periaqueductal grey. Eur J Pharmacol 1992, 216(2):149-156.
88. Compton P., Charuvastra V.C., Ling W. Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent. Drug Alcohol Depend 2001, 63(2):139-146.
89. Aurilio C., Pace M.C., Pota V., et al. Opioids switching with transdermal systems in chronic cancer pain. J Exp Clin Cancer Res 2009, 28:61.
90. Gringauz M., Rabinowitz R., Stav A., Korczyn A.D. Tolerance to the analgesic effect of buprenorphine, butorphanol, nalbuphine, and cyclorphan, and cross-tolerance to morphine. J Anesth 2001, 15(4):204-209.
91. Nemirovsky A., Chen L., Zelman V., Jurna I. The antinociceptive effect of the combination of spinal morphine with systemic morphine or buprenorphine. Anesth Analg 2001, 93(1):197-203.
92. Niv D., Nemirovsky A., Metzner J., Rudick V., Jurna I., Urca G. Antinociceptive effect induced by the combined administration of spinal morphine and systemic buprenorphine. Anesth Analg 1998, 87(3):583-586.
93. Mercadante S., Villari P., Ferrera P., et al. Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine. J Pain Symptom Manage 2006, 32(2):175-179.
94. +. Phys Rev Lett 2007, 99(22):221801.
95. Cowan A. Buprenorphine: new pharmacological aspects. Int J Clin Pract Suppl 2003, (133):3-8. 23-24.
96. Kögel B., Christoph T., Strassburger W., Friderichs E. Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice. Eur J Pain 2005, 9(5):599-611.
97. Greenwald M.K., Johanson C.E., Moody D.E., et al. Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology 2003, 28(11):2000-2009.
98. Evans H.C., Easthope S.E. Transdermal buprenorphine. Drugs 2003, 63(19):1999-2010. 11-12.
99. Likar R., Kayser H., Sittl R. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials. Clin Ther 2006, 28(6):943-952.
100. Nasar M.A., McLeavy M.A., Knox J. An open study of sub-lingual buprenorphine in the treatment of chronic pain in the elderly. Curr Med Res Opin 1986, 10(4):251-255.
101. Wirz S., Wittmann M., Schenk M., et al. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine. Eur J Pain 2009, 13(7):737-743.
102. Tassinari D., Sartori S., Tamburini E., et al. Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature. J Palliat Med 2008, 11(3):492-501.
103. Staritz M., Poralla T., Manns M., Meyer Zum Bϋschenfelde K.H. Effect of modern analgesic drugs (tramadol, pentazocine, and buprenorphine) on the bile duct sphincter in man. Gut 1986, 27(5):567-569.
104. Cuer J.C., Dapoigny M., Ajmi S., et al. Effects of buprenorphine on motor activity of the sphincter of Oddi in man. Eur J Clin Pharmacol 1989, 36(2):203-204.
105. Dahan A., Aarts L., Smith T.W. Incidence, reversal, and prevention of opioid-induced respiratory depression. Anesthesiology 2010, 112(1):226-238.
106. Budd K. High dose buprenorphine for postoperative analgesia. Anaesthesia 1981, 36(9):900-903.
107. Dahan A., Yassen A., Romberg R., et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth 2006, 96(5):627-632.
108. Dahan A., Yassen A., Bijl H., et al. Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth 2005, 94(6):825-834.
109. Dahan A. Opioid-induced respiratory effects: new data on buprenorphine. Palliat Med 2006, 20(suppl 1):S3-S8.
110. Chevillard L., Mégarbane B., Risède P., Baud F.J. Characteristics and comparative severity of respiratory response to toxic doses of fentanyl, methadone, morphine, and buprenorphine in rats. Toxicol Lett 2009, 191(2-3):327-340.
111. Mégarbane B., Marie N., Pirnay S., et al. Buprenorphine is protective against the depressive effects of norbuprenorphine on ventilation. Toxicol Appl Pharmacol 2006, 212(3):256-267.
112. Yassen A., Olofsen E., Kan J., Dahan A., Danhof M. Pharmacokinetic-pharmacodynamic modeling of the effectiveness and safety of buprenorphine and fentanyl in rats. Pharm Res 2008, 25(1):183-193.
113. Mégarbane B., Hreiche R., Pirnay S., Marie N., Baud F.J. Does high-dose buprenorphine cause respiratory depression?: possible mechanisms and therapeutic consequences. Toxicol Rev 2006, 25(2):79-85.
114. Mégarbane B., Vodovar D., Baud F.J. Fatalities in relation to buprenorphine snorting and ethanol co-ingestion: mechanisms of toxicity. Forensic Sci Int 2011, 207(1-3):e59-e60.
115. Reynaud M., Petit G., Potard D., Courty P. Six deaths linked to concomitant use of buprenorphine and benzodiazepines. Addiction 1998, 93(9):1385-1392.
116. Chang Y., Moody D.E. Effect of benzodiazepines on the metabolism of buprenorphine in human liver microsomes. Eur J Clin Pharmacol 2005, 60(12):875-881.
117. Nielsen S., Taylor D.A. The effect of buprenorphine and benzodiazepines on respiration in the rat. Drug Alcohol Depend 2005, 79(1):95-101.
118. Nielsen S., Dietze P., Lee N., Dunlop A., Taylor D. Concurrent buprenorphine and benzodiazepines use and self-reported opioid toxicity in opioid substitution treatment. Addiction 2007, 102(4):616-622.
119. Bridge T.P., Fudala P.J., Herbert S., Leiderman D.B. Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependence. Drug Alcohol Depend 2003, 70(suppl 2):S79-S85.
120. Chiang C.N., Hawks R.L. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend 2003, 70(suppl 2):S39-S47.
121. Kintz P. Deaths involving buprenorphine: a compendium of French cases. Forensic Sci Int 2001, 121(1-2):65-69.
122. Clark N.C., Lintzeris N., Muhleisen P.J. Severe opiate withdrawal in a heroin user precipitated by a massive buprenorphine dose. Med J Aust 2002, 176(4):166-167.
123. Walsh S.L., Preston K.L., Stitzer M.L., Cone E.J., Bigelow G.E. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 1994, 55(5):569-580.
124. Walsh S.L., Preston K.L., Bigelow G.E., Stitzer M.L. Acute administration of buprenorphine in humans: partial agonist and blockade effects. J Pharmacol Exp Ther 1995, 274(1):361-372.
125. Corsenac P., Lagarde E., Gadegbeku B., et al. Road traffic crashes and prescribed methadone and buprenorphine: A French registry-based case-control study. Drug Alcohol Depend 2012, 123(1-3):91-97.
126. Galski T., Williams J.B., Ehle H.T. Effects of opioids on driving ability. J Pain Symptom Manage 2000, 19(3):200-208.
127. Strumpf M., Köhler A., Zenz M., Willweber-Strumpf A., Dertwinkel R., Donner B. Opioids and driving ability [in German]. Schmerz 1997, 11(4):233-240.
128. Lenné M.G., Dietze P., Rumbold G.R., Redman J.R., Triggs T.J. The effects of the opioid pharmacotherapies methadone, LAAM and buprenorphine, alone and in combination with alcohol, on simulated driving. Drug Alcohol Depend 2003, 72(3):271-278.
129. Thomas R.E. Benzodiazepine use and motor vehicle accidents. Systematic review of reported association. Can Fam Physician 1998, 44:799-808.
130. Giacomuzzi S., Haaser W., Pilsz L., Riemer Y. Driving impairment on buprenorphine and slow-release oral morphine in drug-dependent patients. Forensic Sci Int 2005, 152(2-3):323-324.
131. Soyka M., Hock B., Kagerer S., Lehnert R., Limmer C., Kuefner H. Less impairment on one portion of a driving-relevant psychomotor battery in buprenorphine-maintained than in methadone-maintained patients: results of a randomized clinical trial. J Clin Psychopharmacol 2005, 25(5):490-493.
132. Baewert A., Gombas W., Schindler S.D., et al. Influence of peak and trough levels of opioid maintenance therapy on driving aptitude. Eur Addict Res 2007, 13(3):127-135.
133. Sabatowski R. Driving ability under opioids: current assessment of published studies [in German]. Dtsch Med Wochenschr 2008, 133(suppl 2):S25-S28.
134. Shmygalev S., Damm M., Weckbecker K., Berghaus G., Petzke F., Sabatowski R. The impact of long-term maintenance treatment with buprenorphine on complex psychomotor and cognitive function. Drug Alcohol Depend 2011, 117(2-3):190-197.
135. Dagtekin O., Gerbershagen H.J., Wagner W., Petzke F., Radbruch L., Sabatowski R. Assessing cognitive and psychomotor performance under long-term treatment with transdermal buprenorphine in chronic noncancer pain patients. Anesth Analg 2007, 105(5):1442-1448.
136. Radbruch L. Buprenorphine TDS: use in daily practice, benefits for patients. Int J Clin Pract Suppl 2003, (133):19-22. 23-24.
137. Brinkman W.J., Hall D.M., Suo J.L., Weber R.J. Centrally-mediated opioid-induced immunosuppression. Elucidation of sympathetic nervous system involvement. Adv Exp Med Biol 1998, 437:43-49.
138. Vallejo R., de Leon-Casasola O., Benyamin R. Opioid therapy and immunosuppression: a review. Am J Ther 2004, 11(5):354-365.
139. Wang J., Barke R.A., Roy S. Transcriptional and epigenetic regulation of interleukin-2 gene in activated T cells by morphine. J Biol Chem 2007, 282(10):7164-7171.
140. Sacerdote P. Opioids and the immune system. Palliat Med 2006, 20(suppl 1):S9-S15.
141. Sacerdote P. Opioid-induced immunosuppression. Curr Opin Support Palliat Care 2008, 2(1):14-18.
142. Shavit Y., Ben-Eliyahu S., Zeidel A., Beilin B. Effects of fentanyl on natural killer cell activity and on resistance to tumor metastasis in rats. Dose and timing study. Neuroimmunomodulation 2004, 11(4):255-260.
143. Budd K. Pain management: is opioid immunosuppression a clinical problem?. Biomed Pharmacother 2006, 60(7):310-317.
144. Wei G., Moss J., Yuan C.S. Opioid-induced immunosuppression: is it centrally mediated or peripherally mediated?. Biochem Pharmacol 2003, 65(11):1761-1766.
145. Gavériaux-Ruff C., Matthes H.W., Peluso J., Kieffer B.L. Abolition of morphine-immunosuppression in mice lacking the mu-opioid receptor gene. Proc Natl Acad Sci U S A 1998, 95(11):6326-6330.
146. Fecho K., Maslonek K.A., Dykstra L.A., Lysle D.T. Evidence for sympathetic and adrenal involvement in the immunomodulatory effects of acute morphine treatment in rats. J Pharmacol Exp Ther 1996, 277(2):633-645.
147. Franchi S., Panerai A.E., Sacerdote P. Buprenorphine ameliorates the effect of surgery on hypothalamus-pituitary-adrenal axis, natural killer cell activity, and metastatic colonization in rats in comparison with morphine or fentanyl treatment. Brain Behav Immun 2007, 21(6):767-774.
148. Gomez-Flores R., Weber R.J. Differential effects of buprenorphine and morphine on immune and neuroendocrine functions following acute administration in the rat mesencephalon periaqueductal gray. Immunopharmacology 2000, 48(2):145-156.
149. Freier D.O., Fuchs B.A. A mechanism of action for morphine-induced immunosuppression: corticosterone mediates morphine-induced suppression of natural killer cell activity. J Pharmacol Exp Ther 1994, 270(3):1127-1133.
150. Limiroli E., Gaspani L., Panerai A.E., Sacerdote P. Differential morphine tolerance development in the modulation of macrophage cytokine production in mice. J Leukoc Biol 2002, 72(1):43-48.
151. Martucci C., Panerai A.E., Sacerdote P. Chronic fentanyl or buprenorphine infusion in the mouse: similar analgesic profile but different effects on immune responses. Pain 2004, 110(1-2):385-392.
152. Fecho K., Maslonek K.A., Dykstra L.A., Lysle D.T. Assessment of the involvement of central nervous system and peripheral opioid receptors in the immunomodulatory effects of acute morphine treatment in rats. J Pharmacol Exp Ther 1996, 276(2):626-636.
153. Tartter P.I., Steinberg B., Barron D.M., Martinelli G. The prognostic significance of natural killer cytotoxicity in patients with colorectal cancer. Arch Surg 1987, 122(11):1264-1268.
154. Koda K., Saito N., Takiguchi N., Oda K., Nunomura M., Nakajima N. Preoperative natural killer cell activity: correlation with distant metastases in curatively research colorectal carcinomas. Int Surg 1997, 82(2):190-193.
155. Levy S., Herberman R., Lippman M., d'Angelo T. Correlation of stress factors with sustained depression of natural killer cell activity and predicted prognosis in patients with breast cancer. J Clin Oncol 1987, 5(3):348-353.
156. Schantz S.P., Savage H.E., Racz T., Taylor D.L., Sacks P.G. Natural killer cells and metastases from pharyngeal carcinoma. Am J Surg 1989, 158(4):361-366.
157. Fujisawa T., Yamaguchi Y. Autologous tumor killing activity as a prognostic factor in primary resected non-small cell carcinoma of the lung. Cancer 1997, 79(3):474-481.
158. Atzpodien J., Kirchner H., Korfer A., et al. Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-alpha-2. Tumour Biol 1993, 14(6):354-359.
159. Page G.G., Ben-Eliyahu S., Yirmiya R., Liebeskind J.C. Morphine attenuates surgery-induced enhancement of metastatic colonization in rats. Pain 1993, 54(1):21-28.
160. Page G.G., Ben-Eliyahu S., Liebeskind J.C. The role of LGL/NK cells in surgery-induced promotion of metastasis and its attenuation by morphine. Brain Behav Immun 1994, 8(3):241-250.
161. Page G.G., McDonald J.S., Ben-Eliyahu S. Preoperative versus postoperative administration of morphine: impact on the neuroendocrine, behavioural, and metastatic-enhancing effects of surgery. Br J Anaesth 1998, 81(2):216-223.
162. Page G.G., Blakely W.P., Ben-Eliyahu S. Evidence that postoperative pain is a mediator of the tumor-promoting effects of surgery in rats. Pain 2001, 90(1-2):191-199.
163. Lewis J.W., Shavit Y., Terman G.W., Gale R.P., Liebeskind J.C. Stress and morphine affect survival of rats challenged with a mammary ascites tumor (MAT 13762B). Nat Immun Cell Growth Regul 1983, 3(1):43-50.
164. Page G.G. Surgery-induced immunosuppression and postoperative pain management. AACN Clin Issues 2005, 16(3):302-309. 416-418.
165. Exadaktylos A.K., Buggy D.J., Moriarty D.C., Mascha E., Sessler D.I. Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis?. Anesthesiology 2006, 105(4):660-664.
166. Biki B., Mascha E., Moriarty D.C., Fitzpatrick J.M., Sessler D.I., Buggy D.J. Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: a retrospective analysis. Anesthesiology 2008, 109(2):180-187.
167. D'Elia M., Patenaude J., Hamelin C., Garrel D.R., Bernier J. No detrimental effect from chronic exposure to buprenorphine on corticosteroid-binding globulin and corticosensitive immune parameters. Clin Immunol 2003, 109(2):179-187.
168. Sacerdote P., Franchi S., Gerra G., Leccese V., Panerai A.E., Somaini L. Buprenorphine and methadone maintenance treatment of heroin addicts preserves immune function. Brain Behav Immun 2008, 22(4):606-613.
169. Neri S., Bruno C.M., Pulvirenti D., et al. Randomized clinical trial to compare the effects of methadone and buprenorphine on the immune system in drug abusers. Psychopharmacology (Berl) 2005, 179(3):700-704.
170. Welters I. Opioids and immunosuppression. Clinical relevance? [in German]. Anaesthesist 2003, 52(5):442-452.
171. Paice J.A., Penn R.D., Ryan W.G. Altered sexual function and decreased testosterone in patients receiving intraspinal opioids. J Pain Symptom Manage 1994, 9(2):126-131.
172. Nelson R.E., Nebeker J.R., Sauer B.C., Lafleur J. Factors associated with screening or treatment initiation among male United States veterans at risk for osteoporosis fracture. Bone 2012, 50(4):983-988.
173. Ceccarelli I., De Padova A.M., Fiorenzani P., Massafra C., Aloisi A.M. Single opioid administration modifies gonadal steroids in both the CNS and plasma of male rats. Neuroscience 2006, 140(3):929-937.
174. Aloisi A.M., Buonocore M., Merlo L., et al. Chronic pain therapy and hypothalamic-pituitary-adrenal axis impairment. Psychoneuroendocrinology 2011, 36(7):1032-1039.
175. Aloisi A.M., Ceccarelli I., Carlucci M., et al. Hormone replacement therapy in morphine-induced hypogonadic male chronic pain patients. Reprod Biol Endocrinol 2011, 9:26.
176. Bliesener N., Albrecht S., Schwager A., Weckbecker K., Lichtermann D., Klingmuller D. Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence. J Clin Endocrinol Metab 2005, 90(1):203-206.
177. Hallinan R., Byrne A., Agho K., McMahon C.G., Tynan P., Attia J. Hypogonadism in men receiving methadone and buprenorphine maintenance treatment. Int J Androl 2009, 32(2):131-139.
178. Hallinan R., Byrne A., Agho K., McMahon C., Tynan P., Attia J. Erectile dysfunction in men receiving methadone and buprenorphine maintenance treatment. J Sex Med 2008, 5(3):684-692.
179. Aurilio C., Ceccarelli I., Pota V., et al. Endocrine and behavioural effects of transdermal buprenorphine in pain-suffering women of different reproductive ages. Endocr J 2011, 58(12):1071-1078.
180. Krantz M.J., Martin J., Stimmel B., Mehta D., Haigney M.C. QTc interval screening in methadone treatment. Ann Intern Med 2009, 150(6):387-395.
181. Anchersen K., Clausen T., Gossop M., Hansteen V., Waal H. Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study. Addiction 2009, 104(6):993-999.
182. Athanasos P., Farquharson A.L., Compton P., Psaltis P., Hay J. Electrocardiogram characteristics of methadone and buprenorphine maintained subjects. J Addict Dis 2008, 27(3):31-35.
183. Wedam E.F., Bigelow G.E., Johnson R.E., Nuzzo P.A., Haigney M.C. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med 2007, 167(22):2469-2475.
184. Bell J.R., Butler B., Lawrance A., Batey R., Salmelainen P. Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend 2009, 104(1-2):73-77.
185. Crook J., Rideout E., Browne G. The prevalence of pain complaints in a general population. Pain 1984, 18(3):299-314.
186. Graf J. Analgesic use in the elderly: the "pain" and simple truth: comment on "The comparative safety of analgesics in older adults with arthritis". Arch Intern Med 2010, 170(22):1976-1978.
187. Todd B. Narcotic analgesics for chronic pain. Drugs and the elderly. Geriatr Nurs 1986, 7(1):53-55.
188. Wall R.T. Use of analgesics in the elderly. Clin Geriatr Med 1990, 6(2):345-364.
189. Fick D.M., Cooper J.W., Wade W.E., Waller J.L., Maclean J.R., Beers M.H. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003, 163(22):2716-2724.
190. Muriel Villoria C., Pérez-Castejón Garrote J.M., Sánchez Magro I., Neira Alvarez M. Effectiveness and safety of transdermal buprenorphine for chronic pain treatment in the elderly: a prospective observational study [in Spanish]. Med Clin (Barc) 2007, 128(6):204-210.
191. Hand C.W., Sear J.W., Uppington J., Ball M.J., McQuay H.J., Moore R.A. Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites. Br J Anaesth 1990, 64(3):276-282.
192. Iribarne C., Berthou F., Carlhant D., et al. Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors. Drug Metab Dispos 1998, 26(3):257-260.
193. Seripa D., Pilotto A., Panza F., Matera M.G., Pilotto A. Pharmacogenetics of cytochrome P450 (CYP) in the elderly. Ageing Res Rev 2010, 9(4):457-474.
194. Mistry M., Houston J.B. Glucuronidation in vitro and in vivo. Comparison of intestinal and hepatic conjugation of morphine, naloxone, and buprenorphine. Drug Metab Dispos 1987, 15(5):710-717.
195. Vestergaard P., Rejnmark L., Mosekilde L. Fracture risk associated with the use of morphine and opiates. J Intern Med 2006, 260(1):76-87.
196. Böger R.H. Renal impairment: a challenge for opioid treatment?. The role of buprenorphine. Palliat Med 2006, 20(suppl 1):S17-S23.
197. Filitz J., Griessinger N., Sittl R., Likar R., Schϋttler J., Koppert W. Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine. Eur J Pain 2006, 10(8):743-748.
198. Likar R. Transdermal buprenorphine in the management of persistent pain-safety aspects. Ther Clin Risk Manag 2006, 2(1):115-125.
199. Wanigasekera V., Lee M.C., Rogers R., Hu P., Tracey I. Neural correlates of an injury-free model of central sensitization induced by opioid withdrawal in humans. J Neurosci 2011, 31(8):2835-2842.
200. Jasinski D.R., Pevnick J.S., Griffith J.D. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry 1978, 35(4):501-516.
201. Walsh S.L., Eissenberg T. The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug Alcohol Depend 2003, 70(suppl 2):S13-S27.
202. Walsh S.L., June H.L., Schuh K.J., Preston K.L., Bigelow G.E., Stitzer M.L. Effects of buprenorphine and methadone in methadone-maintained subjects. Psychopharmacology (Berl) 1995, 119(3):268-276.
203. Robinson S.E. Buprenorphine: an analgesic with an expanding role in the treatment of opioid addiction. CNS Drug Rev 2002, 8(4):377-390.
204. Rosado J., Walsh S.L., Bigelow G.E., Strain E.C. Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone. Drug Alcohol Depend 2007, 90(2-3):261-269.
205. Stoller K.B., Bigelow G.E., Walsh S.L., Strain E.C. Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology (Berl) 2001, 154(3):230-242.
206. Johnson R.E., Cone E.J., Henningfield J.E., Fudala P.J. Use of buprenorphine in the treatment of opiate addiction. I. Physiologic and behavioral effects during a rapid dose induction. Clin Pharmacol Ther 1989, 46(3):335-343.
207. Jasinski D.R., Fudala P.J., Johnson R.E. Sublingual versus subcutaneous buprenorphine in opiate abusers. Clin Pharmacol Ther 1989, 45(5):513-519.
208. Strain E.C., Preston K.L., Liebson I.A., Bigelow G.E. Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers. J Pharmacol Exp Ther 1992, 261(3):985-993.
209. Amass L., Kamien J.B., Mikulich S.K. Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans. Drug Alcohol Depend 2001, 61(2):173-181.
210. Bouchez J., Beauverie P., Touzeau D. Substitution with buprenorphine in methadone- and morphine sulfate-dependent patients. Preliminary results. Eur Addict Res 1998, 4(suppl 1):S8-S12.
211. Law F.D., Nutt D.J. Maintenance buprenorphine for opioid users. Lancet 2003, 361(9358):634-635.
212. Levin F.R., Fischman M.W., Connerney I., Foltin R.W. A protocol to switch high-dose, methadone-maintained subjects to buprenorphine. Am J Addict 1997, 6(2):105-116.
213. Jones H.E. Practical considerations for the clinical use of buprenorphine. Sci Pract Perspect 2004, 2(2):4-20.
214. Welsh C.J., Suman M., Cohen A., Broyles L., Bennett M., Weintraub E. The use of intravenous buprenorphine for the treatment of opioid withdrawal in medically ill hospitalized patients. Am J Addict 2002, 11(2):135-140.
215. Gowing L., Ali R., White J. Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev 2004, (4). CD002025.
216. Bekkering G.E., Soares-Weiser K., Reid K., et al. Can morphine still be considered to be the standard for treating chronic pain?. A systematic review including pair-wise and network meta-analyses. Curr Med Res Opin 2011, 27(7):1477-1491.
217. Hass B., Lungershausen J., Hertel N., Poulsen Nautrup B., Kotowa W., Liedgens H. Cost-effectiveness of strong opioids focussing on the long-term effects of opioid-related fractures: a model approach. Eur J Health Econ 2009, 10(3):309-321.